Neural-network interpretation identifies a metabolic panel associated with Moyamoya disease
Source check: Source checked. Not independent scientific confirmation.
Finding: A neural network learned serum patterns distinguishing Moyamoya disease from healthy controls. Model interpretation helped select six metabolic signals; their later three-center evaluation reported AUC 0.867, rather than the higher full-fingerprint result.
Technology: Neural network; integrated gradients
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The network learns diagnostic patterns; integrated gradients guides signal selection alongside statistical comparisons.
- Test and result
- Discovery data comprised 144 patients and 144 controls; repeated spectra were averaged per sample. The six-signal panel was evaluated in 86 later samples, including 49 cases.
- Limitation / still unknown
- Selected case-control evaluation; preprocessing and feature-selection nesting are incompletely established. Metabolite assignments are tentative. No population screening, stroke prevention or mechanistic claim.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://advanced.onlinelibrary.wiley.com/doi/10.1002/advs.202405580 · https://pmc.ncbi.nlm.nih.gov/articles/PMC11848555/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Primary front identity/date and relevant clinical/model Methods and classification Results; operational sample procedures excluded..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.